Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.
Identification of Nucleobindin-2 as a Potential Biomarker for Breast Cancer Metastasis Using iTRAQ-based Quantitative Proteomic Analysis.
复制标题
使用基于 iTRAQ 的定量蛋白质组分析鉴定 Nucleobindin-2 作为乳腺癌转移的潜在生物标志物
DOI：
10.7150/jca.19619
复制
发表时间：
2017
影响因子：
3.9
通讯作者：
Deng X
中科院分区：
文献类型：
--
作者：
Zeng L;Zhong J;He G;Li F;Li J;Zhou W;Liu W;Zhang Y;Huang S;Liu Z;Deng X
转移是乳腺癌进展中的致命步骤。到目前为止，没有一种转移相关的生物标志物在乳腺癌患者中具有明确的预后价值。本研究旨在确定乳腺癌转移的生物标志物和乳腺癌患者预后的预测因子。采用iTRAQ蛋白质组学定量分析方法，对23对乳腺癌原发灶和转移淋巴结进行蛋白质组学鉴定。采用免疫组化法对106例乳腺癌原发灶和转移淋巴结组织中NUCB 2的表达进行定位和检测。采用χ 2检验分析NUCB 2表达与乳腺癌患者临床病理特征的关系。采用Kaplan-Meier分析和考克斯风险回归分析探讨其表达与乳腺癌患者预后的关系。iTRAQ蛋白质组学结果显示，鉴定出4，837个机密蛋白质，其中643个在原发性乳腺癌组织和配对转移淋巴结中差异表达。NUCB 2蛋白在配对转移淋巴结中表达降低（P = 0.000），在乳腺癌原发灶和配对转移淋巴结中的阳性表达率分别为82%和47%。经Kaplan-Meier分析，NUCB 2蛋白表达阳性患者的总生存期短于NUCB 2蛋白表达阴性患者（P = 0.004）。考克斯回归模型提示NUCB 2是乳腺癌患者的危险因素（P = 0.045，RR = 1.854）。我们的结论是，NUCB 2可以作为一个潜在的生物标志物乳腺癌转移和乳腺癌患者的预后预测。
Metastasis is a lethal step in the progression of breast cancer. None of the metastasis-associated biomarkers identified up to now has a definite prognostic value in breast cancer patients. This study was designed to identify biomarkers for breast cancer metastasis and predictors of the prognosis of breast cancer patients. The differentially expressed proteins between 23 paired primary breast tumor and metastatic lymph nodes were identified by quantitative iTRAQ proteomic analysis. Immunohistochemistry was applied to locate and assess the expression of NUCB2 in paired primary breast tumor and metastatic lymph node tissues (n = 106). The relationship between NUCB2 expression and the clinicopathological characteristics of breast cancer patients (n = 189) were analyzed by χ2 test. Kaplan-Meier analysis and Cox hazard regression analysis were utilized to investigate the relationship between its expression and prognosis of breast cancer patients. The iTRAQ proteomic results showed that 4,837 confidential proteins were identified, 643 of which were differentially expressed in the primary breast cancer tissues and the paired metastatic lymph nodes. NUCB2 protein was found decreased in paired metastatic lymph nodes (P = 0.000), with the positive expression rate being 82% in primary breast cancer tissues and 47% in paired metastatic lymph nodes, respectively. According to Kaplan-Meier analysis, the overall survival time of patients with positive expression of NUCB2 protein were shorter than those with negative NUCB2 expression (P = 0.004). Cox regression model suggested that NUCB2 was a risk factor of breast cancer patients (P = 0.045, RR = 1.854). We conclude that NUCB2 can be used as a potential biomarker for breast cancer metastasis and a prognostic predictor of breast cancer patients.
登录
查看更多内容
影响因子：
3.7
作者：
Boutté AM;McDonald WH;Shyr Y;Yang L;Lin PC
通讯作者：
Lin PC
DOI：
10.1055/s-0033-1351324
发表时间：
2013-12
期刊：
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
影响因子：
--
作者：
Stengel A;Taché Y
通讯作者：
Taché Y
影响因子：
4.4
作者：
Bouchal, Pavel;Roumeliotis, Theodoros;Garbis, Spiros D.
通讯作者：
Garbis, Spiros D.
影响因子：
11.2
作者：
Fayard, Berengere;Bianchi, Fabrizio;Monard, Denis
通讯作者：
Monard, Denis
DOI：
10.1016/j.bbrc.2005.10.064
发表时间：
2005-12-16
影响因子：
3.1
作者：
Kim, MJ;Yoo, YA;Yoo, YD
通讯作者：
Yoo, YD